Independent Dose Verification Research Articles

An automation of Monte Carlo workflow for dosimetry study of an Elekta LINAC delivery system in radiotherapy

PurposeThis study aims to automate the Monte Carlo (MC) workflow utilized for radiotherapy dosimetry, focusing on an Elekta LINAC delivery system. It addresses the challenge of integrating MC simulations into routine clinical practice, making this accurate yet complex method more accessible and efficient for radiotherapy dosimetry. Methods and MaterialsWe developed a user-friendly software featuring a graphical user interface (GUI) that integrates EGSnrc for MC simulations. The software streamlines the process from retrieving Digital Imaging and Communications in Medicine (DICOM) data to executing dose calculations and comparing dose distributions. To validate our proposed tool, we compared its computed doses for IMRT and VMAT plans from the Pinnacle TPS for an Elekta Versa HD linear accelerator against MC simulation results. This comparison utilized our in-house software and GUI as the tool, covering various treatment sites and prescriptions. ResultsThe automated MC workflow demonstrated high accuracy in dose calculations and streamlined integration with clinical workflows. The comparison between the MC-simulated and TPS-calculated doses revealed excellent agreement, highlighting the reliability of MC for independent dose verification in complex treatment scenarios. ConclusionsThe automated MC workflow developed represents a substantial improvement in the practicality and efficiency of MC simulations in radiotherapy. This advancement not only simplifies the dosimetry process but also ensures high accuracy, establishing it as a valuable tool for routine patient-specific quality assurance and the development of specialized treatment procedures.

Feasibility of a Single-Fraction Stereotactic Dose of 30 Gy to Solitary Lung Lesions on Halcyon.

Purpose We sought to explore the feasibility of using the current co-planar Halcyon ring delivery system (RDS) with a novel multileaf collimator (MLC) aperture shape controller in delivering a single high dose of 30 Gy to solitary lung lesions via stereotactic body radiotherapy (SBRT). Materials and methods Thirteen non-small-cell lung cancer (NSCLC) patients previously treated with a single dose of 30 Gy to lung lesions via SBRT on the TrueBeam (6MV-FFF) using non-coplanar volumetric modulated arc therapy (VMAT) arcs were anonymized and replanned onto the Halcyon RDS (6MV-FFF) following RTOG-0915 single-fraction criteria. The Halcyon plans utilized a novel dynamic conformal arc (DCA)-based MLC-fitting approach before VMAT optimization with a user-defined aperture shape controller option. The clinical TrueBeam and Halcyon plans were compared via their protocol compliance, target conformity, gradient index, and dose to organs-at-risk (OAR). Treatment delivery efficacy and accuracy were assessed through end-to-end quality assurance (QA) tests on Halcyon and independent dose verification via in-house Monte Carlo (MC) second-check validation. Results All Halcyon lung SBRT plans met RTOG-0915 protocol's requirements for target coverage, conformity, and gradient indices, and maximum dose 2 cm away from the target (D2cm) while being statistically insignificant (p > 0.05) when compared to clinical TrueBeam plans. Additionally, Halcyon provided a similar dose to OAR except for the ribs, where Halcyon demonstrated a lower maximum dose (15.22 Gy vs 17.01 Gy, p < 0.001). However, Halcyon plans required a higher total monitor unit (8892 MU vs 7413 MU, p < 0.001), resulting in a higher beam modulation factor (2.96 MU/cGy vs 2.47 MU/cGy, p < 0.001) and an increase in beam-on time by a factor of 2.1 (11.11 min vs 5.3 min, p < 0.005). End-to-end QA measurements demonstrate that Halcyon plans were clinically acceptable with an average gamma passing rate of 99.8% for 2%/2mm criteria and independent MC 2nd checks within ±2.86%. Conclusion Our end-to-end testing and validation study demonstrates that by utilizing a DCA-based MLC aperture shape controller before VMAT optimization, Halcyon can be used for delivering a single dose of lung SBRT treatment. However, future improvements of Halcyon RDS are recommended to allow higher output rates, rotational couch corrections, and an integrated intrafraction motion management system that will further enhance Halcyon's capability for site-specific single dosage of SBRT.

Dose Calculation Accuracy of Beam Models in RadCalc for a 1.5 T MR-Linac

The purpose of this study is to evaluate RadCalc, an independent dose verification software, for patient-specific quality assurance (PSQA) in online adaptive planning with a magnetic resonance linear accelerator (MR-linac) of a 1.5 T. Version 7.1.4 of RadCalc to introduce the capability to establish a beam model that incorporates MR field characteristics. A total of six models were established, with one using manufacturer-provided data and the others differing in percentage depth dose (PDD) data sources. Overall, two models utilized PDD data from the treatment planning system (TPS), and three used commissioned PDD data from gantry angles of 0° and 270°. Simple tests on a virtual water phantom assessed dose-calculation accuracy, revealing percentage differences ranging from −0.5% to −20.6%. Excluding models with significant differences, clinical tests on 575 adaptive plans (prostate, liver, and breast) showed percentage differences of −0.51%, 1.12%, and 4.10%, respectively. The doses calculated using RadCalc demonstrated similar trends to those of the PSQA-based measurements. The newly released version of RadCalc enables beam modeling that considers the characteristics of the 1.5 T magnetic field. The accuracy of the software in calculating doses at 1.5 T magnetic fields has been verified, thereby making it a reliable and effective tool for PSQA in adaptive plans.

Is it necessary to perform measurement-based patient-specific quality assurance for online adaptive radiotherapy with Elekta Unity MR-Linac?

This study aimed to investigate the necessity of measurement-based patient-specific quality assurance (PSQA) for online adaptive radiotherapy by analyzing measurement-based PSQA results and calculation-based 3D independent dose verification results with Elekta Unity MR-Linac. There are two workflows for Elekta Unity enabled in the treatment planning system: adapt to position (ATP) and adapt to shape (ATS). ATP plans are those which have relatively slighter shifts from reference plans by adjusting beam shapes or weights, whereas ATS plans are the new plans optimized from the beginning with probable re-contouring targets and organs-at-risk. PSQA gamma passing rates were measured using an MR-compatible ArcCHECK diode array for 78 reference plans and corresponding 208 adaptive plans (129 ATP plans and 79 ATS plans) of Elekta Unity. Subsequently, the relationships between ATP, or ATS plans and reference plans were evaluated separately. The Pearson's r correlation coefficients between ATP or ATS adaptive plans and corresponding reference plans were also characterized using regression analysis. Moreover, the Bland-Altman plot method was used to describe the agreement of PSQA results between ATP or ATS adaptive plans and reference plans. Additionally, Monte Carlo-based independent dose verification software ArcherQA was used to perform secondary dose check for adaptive plans. For ArcCHECK measurements, the average gamma passing rates (ArcCHECK vs. TPS) of PSQA (3%/2mm criterion) were 99.51%±0.88% and 99.43%±0.54% for ATP and ATS plans, respectively, which were higher than the corresponding reference plans 99.34%±1.04% (p<0.05) and 99.20%±0.71% (p<0.05), respectively. The Pearson's r correlation coefficients were 0.720 between ATP and reference plans and 0.300 between ATS and reference plans with ArcCHECK, respectively. Furthermore,>95% of data points of differences between both ATP and ATS plans and reference plans were within±2σ (standard deviation) of the mean difference between adaptive and reference plans with ArcCHECK measurements. With ArcherQA calculation, the average gamma passing rates (ArcherQA vs. TPS) were 98.23%±1.64% and 98.15%±1.07% for ATP and ATS adaptive plans, separately. It might be unnecessary to perform measurement-based PSQA for both ATP and ATS adaptive plans for Unity if the gamma passing rates of both measurements of corresponding reference plans and independent dose verification of adaptive plans have high gamma passing rates. Periodic machine QA and verification of adaptive plans were recommended to ensure treatment safety.

Development of the Independent Dose Verification Method for the Ring Gantry PET/CT Linac

The RefleXion Xi is a new external beam radiotherapy delivery modality combining kilovoltage fan-beam CT and on-board PET for Biology-guided Radiotherapy. Although the machine shares similar components with the Tomotherapy machine, it has unique hardware features such as stationary beam delivery system with couch increments. The goal of this study is to develop an in-house independent secondary dose calculation method for this ring gantry PET/CT Linac. The method aggregates the beam intensities at each discrete firing gantry angle and couch moving position. The non-uniform intensity map is decomposed into a series of segments of uniform beam intensities, and then coordinates of beam segments were modified based on the relative distance from the dose calculation point to keep the calculation point in the same spot along the gantry rotation. The dose to the calculation point of each segment is determined by using measured tissue-maximum-ratio, output factors, and off-axis ratio by independent binary collimators. Two-dimensional convolution method is applied to integrate all dose contribution components in segment areas for efficient calculation. The final dose is obtained by summing all dose to the calculation point of segments for all firing gantry angle and couch position. Twenty patients with different treatment sites including head and neck, prostate, and lung regions were analyzed. Comparison of the point dose calculated by the independent program to that calculated by the planning system has shown reasonable agreement within ±5%. The independent dose verification program has been developed as an initial patient specific QA for improving patient safety. Further study will be performed to enhance the accuracy and reliability by including additional leakage and scatter models.

Advantages of Implementing Sliding Window Gamma Thresholding to Traditional QA Methods

Recent recommendations on gamma passing criteria from the AAPM's TG-218/TG-219 for patient quality assurance are crucial in our endeavor for standardization. The need for standardization is important as demonstrated by the TG 218's review of different reported criteria in dose volume comparisons. However, the need for a standardized use of a low dose threshold leaves an important question to be investigated to ensure a high sensitivity for error detection and an increasingly robust analysis of patient quality assurance. The objective of this work is to provide evidence that a multi-level dose threshold gamma evaluation should be further investigated and that implementing the suggested 10% threshold could conceivably wash out failing points in areas of higher importance. Five patients plans computed with collapsed cone in the TPS were exported and computed with an independent calculation-based dose verification system also using a collapsed cone algorithm. In addition, these patients were also measured with a surrogate quality assurance detector. For the independent calculation, a 2%/2mm gamma criteria was used. For the detector measurements a 3%/3mm criteria was used. Both methods were evaluated with a sliding threshold incremented in several steps of maximum dose from 0-98%. Four of the five patients plans evaluated had possible issues with QA performance. Three (60%) of the patient plans, one of which is included in the table below, demonstrated that utilizing a multi-level dose threshold gamma evaluation proved to be a promising tool in identifying plans with potential discrepancies in areas of importance, such as the high dose areas which include the target and abutting OARs. Further investigation and consideration is needed into how the low dose thresholds are utilized when performing gamma comparisons between dose volumes. This work proposes a simple to implement method that will greatly improve how potential errors in treatment planning can be identified. There is promise in future works in progress through our continued work, the work of AAPM TG-360 and requests for vendors to continuously improve the available tools and technology.

A structured FMEA approach to optimizing combinations of plan-specific quality assurance techniques for IMRT and VMAT QA.

Many commercial tools are available for plan-specific quality assurance (QA) of radiotherapy plans, with their functionality assessed in isolation. However, multiple QA tools are required to review the full range of potential errors. It is important to assess their effectiveness in combination with each other to look for ways to both streamline the QA process and to make certain that errors of high impact and/or high occurrence are caught before reaching patient treatment. To develop a structured method to assess the effective risk reduction of combinations of QA methods for IMRT/VMAT treatments. First, a structured prospective risk assessment was performed to establish the major failure modes (FMs) of IMRT/VMAT QA, and assign occurrence (O), severity (S), and baseline detectability (BD) rankings to them. The baseline assumed that chart checks and linear accelerator QA was performed, but no plan-specific secondary dose calculation or measurement was done. Second, the detectability of each FM for two secondary dose calculation methods and four plan measurement methods (point-based dose calculation, Monte-Carlo-based dose calculation, 2D fluence-based measurement, 2.5D phantom-based measurement, log file analysis with dose recalculation, and log file analysis combined with MLC QA) was determined. Third, we used a minimum detectability approach in addition to each FM's occurrence and severity to determine the optimal combination of QA methods.We analyzed the cumulative risk priority number of eight combinations of QA methods. The analysis was done on (1) all FMs, (2) FMs with high severity, (3) FMs with high-risk priority numbers (RPN) of O*S*BD, and (4) on FMs with both high severity and high RPN. Our analysis resulted in 54 FMs, including commissioning, planning, data transfer, and linear accelerator failures. 1D secondary dose calculation plus measurement provided a 19%-22% risk reduction from baseline. 1D/3D secondary dose calculation plus log files created a 25%-32% reduction. 3D secondary dose calculation plus measurement resulted in a 27%-34% reduction. 3D secondary dose calculation plus log files with additional machine QA provided the greatest reduction of 31%-42%. This novel structured approach to comparing combinations of QA methods will allow us to optimize our procedures, with the goal of detecting all clinically significant FMs. Our results show that log-file QA with 3D dose recalculation and supplemental machine QA provides better risk reduction than measurement-based QA. This work builds evidence to justify reducing or eliminating measurement-based PSQA with an independent 3D dose verification, log-file measurement, and appropriate supplementation of machine QA. The process also highlights FMs that cannot be caught by pre-treatment QA, prompting us to consider future directions for on-treatment QA.

Development and clinical application of a GPU-based Monte Carlo dose verification module and software for 1.5 T MR-LINAC.

Adaptive radiotherapy (ART) has made significant advances owing to magnetic resonance linear accelerator (MR-LINAC), which provides superior soft-tissue contrast, fast speed and rich functional magnetic resonance imaging (MRI) to guide radiotherapy. Independent dose verification plays a critical role in discovering errors, while several challenges remain in MR-LINAC. A Monte Carlo-based GPU-accelerated dose verification module for Unity is proposed and integrated into the commercial software ArcherQA to achieve fast and accurate quality assurance (QA) for online ART. Electron or positron motion in a magnetic field was implemented, and a material-dependent step-length limit method was used to trade off speed and accuracy. Transport was verified by dose comparison with EGSnrc in three A-B-A phantoms. Then, an accurate Monte Carlo-based Unity machine model was built in ArcherQA, including an MR-LINAC head, cryostat, coils, and treatment couch. In particular, a mixed model combining measured attenuation and homogeneous geometry was adopted for the cryostat. Several parameters in the LINAC model were tuned to commission it in the water tank. An alternating open-closed MLC plan on solid water measured with EBT-XD film was used to verify the LINAC model. Finally, the ArcherQA dose was compared with ArcCHECK measurements and GPUMCD in 30 clinical cases through the gamma test. ArcherQA and EGSnrc were well matched in three A-B-A phantom tests, and the relative dose difference (RDD) was less than 1.6% in the homogenous region. A Unity model was commissioned in the water tank, and the RDD in the homogenous region was less than 2%. In the alternating open-closed MLC plan, the gamma result (3%/3mm) between ArcherQA and Film was 96.55%, better than the gamma result between GPUMCD and Film (92.13%). In 30 clinical cases, the mean three-dimensional (3D) gamma result (3%/2mm) was 99.36%±1.28% between ArcherQA and ArcCHECK for the QA plans and 99.27%±1.04% between ArcherQA and GPUMCD for the clinical patient plans. The average dose calculation time was 106 s in all clinical patient plans. A GPU-accelerated Monte Carlo-based dose verification module was developed and built for the Unity MR-LINAC. The fast speed and high accuracy were proven by comparison with EGSnrc, commission data, the ArcCHECK measurement dose, and the GPUMCD dose. This module can achieve fast and accurate independent dose verification for Unity.

Preliminary evaluation of a novel secondary check tool for intensity modulated radiotherapy treatment planning

PurposeTo evaluate the dosimetric accuracy of the Delta4 Insight (DI) secondary-check dosimetry system. MethodsAbsolute dosimetry in reference conditions, output factors, percent depth doses normalized and off-axis dose profiles for different field sizes calculated by DI were compared with measurements. Dose calculations for 20 clinical IMRT/VMAT plans generated in the TPS using both AAA or AcurosXB algorithms were compared with measurements. The average difference between calculated and measured point dose in high-dose region was calculated for all cases. 3D dose measurements were performed in Delta4 Phantom+ and a comparison between calculated and measured dose distributions was performed by means of the gamma analysis with 3 %/2 mm criteria. The dose distributions calculated by DI for 20 IMRT/VMAT plans were compared with those calculated by the TPS. ResultsThe absolute dosimetry computed by DI showed dose value in agreement with the measured one within 0.3 %. The average differences between measured and calculated output factors were less than 2.5 %. The average PDD differences were less than 0.6 %. An excellent agreement between calculations and off-axis measurements is found. The point doses calculated for the 20 recalculated plan showed good agreement with measurements with average differences less than 0.5 %. The average gamma pass rate values for the Delta4 Phantom + 3D dose analysis was greater than 97.%. The comparison of DI with theTPS showed good agreement for the used metrics. ConclusionsDelta4 Insight may provide a useful independent secondary dose verification system for IMRT/VMAT plans, complementing the traditional global QA protocols.

Do we need patient-specific QA for adaptively generated plans? Retrospective evaluation of delivered online adaptive treatment plans on Varian Ethos.

The clinical introduction of dedicated treatment units for online adaptive radiation therapy (OART) has led to widespread adoption of daily adaptive radiotherapy. OART allows for rapid generation of treatment plans using daily patient anatomy, potentially leading to reduction of treatment margins and increased normal tissue sparing. However, the OART workflow does not allow for measurement of patient-specific quality assurance (PSQA) during treatment delivery sessions and instead relies on secondary dose calculations for verification of adapted plans. It remains unknown if independent dose verification is a sufficient surrogate for PSQA measurements. To evaluate the plan quality of previously treated adaptive plans through multiple standard PSQA measurements. This IRB-approved retrospective study included sixteen patients previously treated with OART at our institution. PSQA measurements were performed for each patient's scheduled and adaptive plans: five adaptive plans were randomly selected to perform ion chamber measurements and two adaptive plans were randomly selected for ArcCHECK measurements. The same ArcCHECK 3D dose distribution was also sent to Mobius3D to evaluate the second-check dosimetry system. All (n=96) ion chamber measurements agreed with the planned dose within 3% with a mean of 1.4% (±0.7%). All (n=48) plans passed ArcCHECK measurements using a 95% gamma passing threshold and 3%/2mm criteria with a mean of 99.1% (±0.7%). All (n=48) plans passed Mobius3D second-check performed with 95% gamma passing threshold and 5%/3mm criteria with a mean of 99.0% (±0.2%). Plan measurement for PSQA may not be necessary for every online-adaptive treatment verification. We recommend the establishment of a periodic PSQA check to better understand trends in passing rates for delivered adaptive treatments.

Effective clinical applications of Monte Carlo-based independent secondary dose verification software for helical tomotherapy

PurposeTo investigate the scope of the effective clinical application of Monte Carlo (MC)-based independent dose verification software for helical tomotherapy. MethodsDoseCHECK was selected as the MC-based dose calculation software. First, the dose calculation accuracy of DoseCHECK was evaluated with film and chamber measurements in a water-equivalent phantom. Second, the dose calculation accuracy was examined in several heterogeneous materials. Finally, dosimetric comparisons between DoseCHECK and the treatment planning system (TPS) were performed for clinical patient plans. Prostate IMRT, head and neck IMRT (HN), total body irradiation (TBI), and brain stereotactic radiotherapy (SRT) were evaluated. ResultThe DoseCHECK calculations agreed with the chamber and film measurements in the homogenous phantom. For heterogeneous phantom cases, the dose differences between DoseCHECK and TPS were within 3 %, except in air, in which large dose differences of 20 % were observed. In clinical patient plans, the median dose differences between the lung Dmean in TBI cases and the normal brain Dmean in brain SRT cases were significantly >3 %. For HN and brain SRT cases, the median target dose differences were >3 %. ConclusionOur results show that independent dose verification with the MC algorithm can detect systematic errors caused by the lack of heterogeneity correction in the TPS. In particular, MC-based independent dose verification is required for HN, TBI, and brain SRT cases in helical tomotherapy.

A Novel Lightning Dose Optimizer for Radiosurgery of Irregular-Shaped Arteriovenous Malformations and Pituitary Adenomas

<h3>Purpose/Objective(s)</h3> To demonstrate the clinical feasibility of a novel inverse planning algorithm via dose optimizer (DO) on a treatment planning system (TPS)for generating high-quality treatment plans with significantly faster planning times for Stereotactic Radiosurgery (SRS) of the complex and difficult cases of arteriovenous malformation (AVM) and pituitary adenomas. <h3>Materials/Methods</h3> After completing the in-house end-to-end phantom testing and independent dose verification of recently upgraded DO on TPS using one institution's IROC anthropomorphic SRS head phantom irradiation credentialing, twenty previously treated SRS patients (10 AVM, average volume 3.61 cc) and (10 pituitary adenomas, average volume 0.86 cc) who underwent manual forward planning on TPS were retrospectively re-planned via DO under IRB protocol. DO finds the target curvature boundary by well formulated linear programming objectives, and inversely optimize SRS plan by isocenter placement, optimization, and sequencing. For identical tumor dose, the DO and original manual plans were compared for target conformity, gradient index, dose to critical organs, and surrounding normal brain. Additionally, various treatment delivery parameters including beam on time were recorded. <h3>Results</h3> For both patient cohorts, DO provided similar target coverage with better dose conformity, tighter radiosurgical dose distribution with lower value of gradient indices (all p < 0.001), and lower dose to critical organs. For AVM, significant reduction of normal brain V10, V12 and V14 by 4.74 cc, 3.67 cc, and 2.67 cc (all p < 0.001), on average via DO was observed at the cost of as many as twice the numbers of shots (p < 0.001), and relatively longer beam on time (p = 0.012) by a factor of 1.44, compared to the clinical manual plans. For pituitary adenoma, DO provided systematically lower values of V10, V12 and V14 by 1.08 cc, 0.86 cc and 0.68 cc (all p < 0.001), on average and lower maximal dose to optic pathway by 0.7 Gy (p = 0.005), but had almost twice the numbers of shots (p < 0.001) and increased beam on time (p = 0.005) by a factor of 1.2, compared to the original manual plans. However, for both patient groups, average planning time for the DO was < 5 minutes, compared to estimated 30-60 min of manual planning times. <h3>Conclusion</h3> SRS treatment via new inverse DO provided highly conformal target coverage, steep dose gradient, spared critical organs, and significantly reduced normal brain dose for complex targets who presented with very irregular nidus or pituitary adenoma. DO generated high quality treatment plans and could yield significant time saving in planning the treatment, particularly for inexperienced SRS users–improving patient compliance, and clinic workflow. If available, DO algorithm is suggested for validation and clinical use for irregular, complex and difficult SRS cases in the future.

Development of independent dose verification plugin using Eclipse scripting API for brachytherapy.

In this study, an independent dose verification plugin (DVP) using the Eclipse Scripting Application Programming Interface (ESAPI) for brachytherapy was developed. The DVP was based on the general 2D formalism reported in AAPM-TG43U1. The coordinate and orientation of each source position were extracted from the translation matrix acquired from the treatment planning system (TPS), and the distance between the source and verification point (r) was calculated. Moreover, the angles subtended by the center-tip and tip-tip of the hypothetical line source with respect to the verification point (θ and β) were calculated. With r, θ, β and the active length of the source acquired from the TPS, the geometry function was calculated. As the TPS calculated the radial dose function, g(r), and 2D anisotropy function, F(r,θ), by interpolating and extrapolating the corresponding table stored in the TPS, the DVP calculated g(r) and F(r,θ) independently from equations fitted with the Monte Carlo data. The relative deviation of the fitted g(r) and F(r,θ) for the GammaMed Plus HDR 192Ir source was 0.5% and 0.9%, respectively. The acceptance range of the relative dose difference was set to ±1.03% based on the relative deviation between the fitted functions and Monte Carlo data, and the linear error propagation law. For 64 verification points from sixteen plans, the mean of absolute values of the relative dose difference was 0.19%. The standard deviation (SD) of the relative dose difference was 0.17%. The DVP maximizes efficiency and minimizes human error for the brachytherapy plan check.

Monte Carlo-based independent dose verification of radiosurgery HyperArc plans

PurposeTo investigate the feasibility of using the free PRIMO Monte Carlo software for independent dose check of cranial SRS plans designed with the Varian HyperArc (HA) technique. Materials and methodsIn this study, the PRIMO Monte Carlo software v. 0.3.64.1800 was used with the phase-space files (v. 2, Feb. 27, 2013) provided by Varian for 6 MV flattening-filter-free (FFF) photon beams from a Varian TrueBeam linear accelerator (linac), equipped with a Millennium 120 multileaf collimator (MLC). This configuration was validated by comparing the percentage depth doses (PDDs), lateral profiles and relative output factors (OFs) simulated in a water phantom against measurements for field sizes from 1 × 1 to 40 × 40 cm2. The agreement between simulated and experimental relative dose curves was evaluated using a global (G) gamma index analysis. In addition, the accuracy of PRIMO to model the MLC was investigated (dosimetric leaf gap, tongue and groove, leaf transmission and interleaf leakage).Thirty-five HA SRS plans computed in the Eclipse treatment planning system (TPS) were simulated in PRIMO. The Acuros XB algorithm v. 16.10 (dose to medium) was used in Eclipse. Sixty targets with diameters ranging from 6 to 33 mm were included. Agreement between the dose distributions given by Eclipse and PRIMO was evaluated in terms of 3D global gamma passing rates (GPRs) for the 2 %/2 mm criteria. ResultsAverage GPR greater than 95 % with the 2 %(G)/1 mm criteria were obtained over the PDD and profiles of each field size. Differences between PRIMO calculated and measured OFs were within 0.5 % in all fields, except for the 1 × 1 cm2 with a discrepancy of 1.5 %. Regarding the MLC modeling in PRIMO, an agreement within 3 % was achieved between calculated and experimental doses. Excellent agreement between PRIMO and Eclipse was found for the 35 HA plans. The 3D global GPRs (2 %/2 mm) for the targets and external patient contour were 99.6 % ± 1.1 % and 99.8 % ± 0.5 %, respectively. ConclusionsAccording to the results described in this study, the PRIMO Monte Carlo software, in conjunction with the 6X FFF Varian phase-space files, can be used as secondary dose calculation software to check stereotactic radiosurgery plans from Eclipse using the HyperArc technique.

Practical guidelines of online MR-guided adaptive radiotherapy.

The first magnetic resonance (MR)-guided radiotherapy system in Japan was installed in May 2017. Implementation of online MR-guided adaptive radiotherapy (MRgART) began in February 2018. Online MRgART offers greater treatment accuracy owing to the high soft-tissue contrast in MR-images (MRI), compared to that in X-ray imaging. The Japanese Society for Magnetic Resonance in Medicine (JSMRM), Japan Society of Medical Physics (JSMP), Japan Radiological Society (JRS), Japanese Society of Radiological Technology (JSRT), and Japanese Society for Radiation Oncology (JASTRO) jointly established the comprehensive practical guidelines for online MRgART. These guidelines propose the essential requirements for clinical implementation of online MRgART with respect to equipment, personnel, institutional environment, practice guidance, and quality assurance/quality control (QA/QC).The minimum requirements for related equipment and QA/QC tools, recommendations for safe operation of MRI system, and the implementation system are described. The accuracy of monitor chamber and detector in dose measurements should be confirmed because of the presence of magnetic field. The ionization chamber should be MR-compatible. Non-MR-compatible devices should be used in an area that is not affected by the static magnetic field (outside the five Gauss line), and their operation should be checked to ensure that they do not affect the MR image quality. Dose verification should be performed using an independent dose verification system that has been confirmed to be reliable through commissioning. This guideline proposes the checklists to ensure the safety of online MRgART. Successful clinical implementation of online MRgART requires close collaboration between physician, radiological technologist, nurse, and medical physicist.

Clinical validation of novel lightning dose optimizer for gamma knife radiosurgery of irregular-shaped arteriovenous malformations and pituitary adenomas.

PurposeTo demonstrate the clinical feasibility of a novel treatment planning algorithm via lightning dose optimizer (LDO) on Leksell Gamma Knife (LGK) GammaPlan with significantly faster planning times for stereotactic radiosurgery (SRS) of the complex and difficult arteriovenous malformations (AVMs) and pituitary adenomas.Methods and materialsAfter completing the in‐house end‐to‐end phantom testing and independent dose verification of the recently upgraded LDO algorithm on GammaPlan using the MD Anderson's IROC anthropomorphic SRS head phantom irradiation credentialing, 20 previously treated GK‐SRS patients (10 AVM, average volume 3.61 cm3 and 10 pituitary adenomas, average volume 0.86 cm3) who underwent manual forward planning on GammaPlan were retrospectively replanned via LDO. These pathologies were included because of the need for adequate dose delivery with organs at risk in very close proximity. LDO finds the target curvature boundary by well‐formulated linear programing objectives and inversely optimizes the GK‐SRS plan by isocenter placement, optimization, and sequencing. For identical target coverage, the LDO and original manual plans were compared for target conformity, gradient index, dose to critical organs, and surrounding normal brain. Additionally, various treatment delivery parameters, including beam‐on time were recorded.ResultsFor both patient cohorts, LDO provided similar target coverage with better dose conformity, tighter radiosurgical dose distribution with a lower value of gradient indices (all p < 0.001), and lower dose to critical organs. For AVMs, there was a significant reduction of normal brain V 10Gy, V 12Gy, and V 14Gy by 4.74, 3.67, and 2.67 cm3 (all p < 0.001). LDO had twice the number of shots (p < 0.001), and longer beam‐on time (p = 0.012) by a factor of 1.44. For pituitary adenomas, LDO provided systematically lower values of V 10Gy, V 12Gy, and V 14Gy by 1.08, 0.86, and 0.68 cm3 (all p < 0.001), and lower maximum dose to optic pathway by 0.7 Gy (p = 0.005), but had almost twice the numbers of shots (p < 0.001) and increased beam‐on time (p = 0.005) by a factor of 1.2. However, for both patient groups, the average planning time for the LDO was <5 min, compared to the estimated 30–90 min of manual planning times.ConclusionGK‐SRS treatment on Leksell Perfexion GammaPlan using the LDO provided highly conformal target coverage with a steep dose gradient, spared critical organs, and significantly reduced normal brain dose for complex targets at the cost of slightly higher treatment times. LDO generated high‐quality treatment plans and could significantly reduce planning time. If available, the LDO algorithm is suggested for validation and clinical use for complex and difficult GK cases.

A polar-coordinate-based pencil beam algorithm for VMAT dose computation with high-resolution gantry angle sampling.

Most commercially available treatment planning systems (TPSs) approximate the continuous delivery of volumetric modulated arc therapy (VMAT) plans with a series of discretized static beams for treatment planning, which can make VMAT dose computation extremely inefficient. In this study, we developed a polar-coordinate-based pencil beam (PB) algorithm for efficient VMAT dose computation with high-resolution gantry angle sampling that can improve the computational efficiency and reduce the dose discrepancy due to the angular under-sampling effect. 6 MV pencil beams were simulated on a uniform cylindrical phantom under an EGSnrc Monte Carlo (MC) environment. The MC-generated PB kernels were collected in the polar coordinate system for each bixel on a fluence map and subsequently fitted via a series of Gaussians. The fluence was calculated using a detectors' eye view with off-axis and MLC transmission factors corrected. Doses of VMAT arc on the phantom were computed by summing the convolution results between the corresponding PB kernels and fluence for each bixel in the polar coordinate system. The convolution was performed using fast Fourier transform to expedite the computing speed. The calculated doses were converted to the Cartesian coordinate system and compared with the reference dose computed by a collapsed cone convolution (CCC) algorithm of the TPS. A heterogeneous phantom was created to study the heterogeneity corrections using the proposed algorithm. Ten VMAT arcs were included to evaluate the algorithm performance. Gamma analysis and computation complexity theory were used to measure the dosimetric accuracy and computational efficiency, respectively. The dosimetric comparisons on the homogeneous phantom between the proposed PB algorithm and the CCC algorithm for 10 VMAT arcs demonstrate that the proposed algorithm can achieve a dosimetric accuracy comparable to that of the CCC algorithm with average gamma passing rates of 96% (2%/2mm) and 98% (3%/3mm). In addition, the proposed algorithm can provide better computational efficiency for VMAT dose computation using a PC equipped with a 4-core processor, compared to the CCC algorithm utilizing a dual 10-core server. Moreover, the computation complexity theory reveals that the proposed algorithm has a great advantage with regard to computational efficiency for VMAT dose computation on homogeneous medium, especially when a fine angular sampling rate is applied. This can support a reduction in dose errors from the angular under-sampling effect by using a finer angular sampling rate, while still preserving a practical computing speed. For dose calculation on the heterogeneous phantom, the proposed algorithm with heterogeneity corrections can still offer a reasonable dosimetric accuracy with comparable computational efficiency to that of the CCC algorithm. We proposed a novel polar-coordinate-based pencil beam algorithm for VMAT dose computation that enables a better computational efficiency while maintaining clinically acceptable dosimetric accuracy and reducing dose error caused by the angular under-sampling effect. It also provides a flexible VMAT dose computation structure that allows adjustable sampling rates and direct dose computation in regions of interest, which makes the algorithm potentially useful for clinical applications such as independent dose verification for VMAT patient-specific QA.

Toward 3D dose verification of an electronic brachytherapy source with a plastic scintillation detector.

BackgroundElectronic brachytherapy (eBT) is considered a safe treatment with good outcomes. However, eBT lacks standardized and independent dose verification, which could impede future use.PurposeTo validate the 3D dose‐to‐water distribution of an electronic brachytherapy (eBT) source using a small‐volume plastic scintillation detector (PSD).MethodsThe relative dose distribution of a Papillon 50 (P50) (Ariane Medical Systems, UK) eBT source was measured in water with a PSD consisting of a cylindrical scintillating BCF‐12 fiber (length: 0.5 mm, Ø: 1 mm) coupled to a photodetector via an optical fiber. The measurements were performed with the PSD mounted on a motorized stage in a water phantom (MP3) (PTW, Germany). This allowed the sensitive volume of the PSD to be moved to predetermined positions relative to the P50 applicator, which pointed vertically downward while just breaching the water surface. The percentage depth‐dose (PDD) was measured from 0 to 50 mm source‐to‐detector distance (SDD) in 1–3 mm steps. Dose profiles were measured along two perpendicular axes at five different SDDs with step sizes down to 0.5 mm. Characterization of the PSD consisted of determining the energy correction through Monte Carlo (MC) simulation and by measuring the stability and dose rate linearity using a well‐type ionization chamber as a reference. The measured PDD and profiles were validated with corresponding MC simulations.ResultsThe measured and simulated PDD curves agreed within 2% (except at 0 mm and 43 mm depth) after the PSD measurements were corrected for energy dependency. The absorbed dose decreased by a factor of 2 at 7 mm depth and by a factor of 10 at 26 mm depth. The measured dose profiles showed dose gradients at the profile edges of more than 50%/mm at 5 mm depth and 15%/mm at 50 mm depth. The measured profile widths increased 0.66 mm per 1 mm depth, while the simulated profile widths increased 0.74 mm per 1 mm depth. An azimuthal dependency of > 10% was observed in the dose at 10 mm distance from the beam center. The total uncertainty of the measured relative dose is < 2.5% with a positional uncertainty of 0.4 mm. The measurements for a full 3D dose characterization (PDD and profiles) can be carried out within 8 h, the limiting factor being cooling of the P50.ConclusionThe PSD and MP3 water phantoms provided a method to independently verify the relative 3D dose distribution in water of an eBT source.

Development and validation of an automatic commissioning tool for the Monte Carlo dose engine in myQA iON

Independent dose verification with Monte Carlo (MC) simulations is an important feature of proton therapy quality assurance (QA). However, clinical integration of such tools often generates an additional and complex workload for medical physicists. The preparation of the necessary clinical inputs, such as the machine beam model, should therefore be automated. In this work, a methodology for automatic MC commissioning has been devised, validated, and developed into a MATLAB tool for the users of myQA iON, the recent QA platform of IBA Dosimetry. With this workflow, all necessary parameters can easily be tuned using dedicated optimization methods. For the geometrical beam parameters (phase space), the assumption of a single or double Gaussian is made. To model the energy spectrum, a Gaussian function is assumed and parameters are optimized using either MC simulations or a library of pre-computed Bragg peaks. For the absolute dose calibration, commissioning fields can be reproduced with the dose engine to retrieve the necessary parameters. We discuss in a first time the tool efficiency and show that one can optimize all parameters in less than 4 min per energy with excellent accuracy. We then validate a beam model obtained with the tool by simulating homogeneous spread-out Bragg peaks (SOBPs) and patient QA plans previously measured in water. An average range agreement of 0.29 ± 0.34 mm is achieved for the SOBPs while 3%/3 mm local gamma passing rates reach 99.3% on average over all 62 measured patient QA planes, which is well within clinical tolerances.

Feasibility Study of Stereotactic Radiosurgery Treatment of Glomus Jugulare Tumors via HyperArc VMAT.

This study aims to report on the clinical validation and feasibility of utilizing a novel fully automated treatment planning and delivery system, HyperArc VMAT stereotactic radiosurgery (SRS) for glomus jugulare tumors (GJT). Independent dose verification of the HyperArc module via the MD Anderson's SRS head phantom irradiation and credentialing results showed compliance with the SRS treatment requirements per IROC MD Anderson's standard. Following the Alliance clinical trial, AAPM, RTOG protocols, and QUANTEC requirements, utilizing selected three-partial arc geometry of HyperArc module on TrueBeam Linac with 6MV-FFF beam, GJT SRS plans were generated for nine previously treated Gamma Knife (GK) radiosurgery patients using advanced Acuros-based algorithm to account for tissue inhomogeneity corrections and frameless immobilization with Q-fix mask and Encompass device insert. HyperArc VMAT produced highly conformal SRS dose distributions to GJT, a steep dose gradient around the GJT, and spared adjacent critical organs including the spinal cord (< 3.0 Gy). Due to faster patient setup and less MLC modulation through the target (average beam-on time, 6.2 minutes), the HyperArc VMAT plan can deliver a single high-dose of 18 Gy to the GJT in less than 15 minutes overall treatment time, significantly improving patient comfort and clinic workflow. Pretreatment portal dosimetry quality assurance results and independent dose verification via Monte Carlo-based physics second check met our clinical SRS protocol's requirements for treatment. Due to the highly conformal dose distribution, rapid dose fall-off, excellent sparing of adjacent critical organs, and highly precise and accurate treatment, clinical implementation of frameless HyperArc VMAT for GJT patients who may not have access to nor tolerate frame-based GK SRS treatment are underway.